Yale Study Links Obesity to Colon Cancer Growth
Obesity is on the rise worldwide and is related to the incidence of colon cancer , but its mechanism has been a mystery. In a new study, Yale University research discovered how obesity drives tumor growth in mice and revealed potential strategies to combat this cancer pathogenesis.
The team studied mice implanted with genetic models of tumors or colon cancer. The researchers first studied the effect of a high-fat diet on mice. Then they gave the mice one of two drugs: one was the controlled release mitochondrial proton mass (CRMP), and the other was metformin (the world’s most commonly used diabetes prescription drug), which burns fat in the liver drug.
The team found that high levels of insulin are the link between obesity and colon cancer. Insulin increases glucose uptake in tumors and promotes tumor growth. The researchers also found that both drugs can reduce insulin levels and slow tumor growth in mice.
The researchers say that this study is the first to demonstrate that obesity-induced high insulin levels drive colon cancer by increasing glucose uptake in these models. Although further research is needed to confirm whether these findings are applicable to humans, insulin reduction therapy: metformin, CRMP , And even exercise can help slow or prevent colon cancer.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Dr. Nishant Mittal
Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. Significant contributions to stem cell biology, developmental biology, and innovative research techniques mark his career. Research Highlights Dr. Mittal's research has focused on several key areas: 1) Cardio…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.